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Regulation (EC) No 726/2004 
REGULATION (EC) No 726/2004 OF THE 
EUROPEAN PARLIAMENT AND OF THE 
COUNCIL
of 31 March 2004
laying down Community procedures for the 
authorisation and supervision of medicinal 
products for human and veterinary use –and-
establishing a European Medicines Agency
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Article 58 of Regulation (EC) No 726/2004
Allows the EMEAs Committee for Medicinal Products 
for Human Use (CHMP) to give scientific 
opinions/advice on medicinal products that are 
intended exclusively for markets outside of the EU
Procedure in cooperation with the World Health 
Organization (WHO) only
Key philosophy – assist developing countries
Same data requirements, procedure and overall
benefit / risk ratio as for EU medicines
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Article 58 of Regulation (EC) No 726/2004




Allows rapid access to non-EU-member countries for 
important new medicinal products
New vaccines may be licensed first in developing 
countries and not in the producing country
Does not exclude future application for MA in the 
Community
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Guideline EMEA/CHMP/5579/04 on Article 58
GUIDELINE ON PROCEDURAL ASPECTS REGARDING 
A CHMP SCIENTIFIC OPINION IN THE CONTEXT OF 
COOPERATION WITH THE WORLD HEALTH 
ORGANISATION (WHO) FOR THE EVALUATION OF 
MEDICINAL PRODUCTS INTENDED EXCLUSIVELY 
FOR MARKETS OUTSIDE THE COMMUNITY 
mirrors the centralised procedure for initial 
assessment of the dossier
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EMEA should provide advice for 
vaccines/medicines of major public interest 
Vaccines for (possible) use in the WHO Expanded 
Programme on Immunization (EPI)
Vaccines for protection against a WHO public health 
priority disease
Vaccines that are part of a WHO stockpile for 
emergency response
Medicines for WHO target diseases such as 
HIV/AIDS, malaria, or tuberculosis. 
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Vaccines industry faces a number of serious problems 
and needs supportive action by all interested parties
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Different vaccines for different reasons needed 
in Developing Countries
Combined vaccines with whole-cell pertussis
Combined vaccines with mening. A/C component
Combined vaccines with fewer components
Oral Polio Vaccine and BCG Vaccine
Multidose vaccines with thiomersal
Monovalent Measles Vaccine
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Evidence of the applicant or a contact point in EEA
SPC or draft product profile
Justification for product’s eligibility




ELIGIBILITY FOR A CHMP SCIENTIFIC OPINION
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Existing procedural guidance for SA applies
See EMEA Website “Scientific Advice”
Same fee applies
Total or partial fee exemptions may be granted
SCIENTIFIC ADVICE (SA)
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Detailed description of procedure for submission in 
guideline
Pre-Opinion inspections: GMP, GCP and GLP
CHMP carries out a scientific assessment of 
applications submitted under Article 58 and adopts
a scientific opinion 
No marketing authorisation granted in Europe (i.e., 
No Commission Decision according to article 10)
A summary of opinion is published at the time of 
adoption of the opinion
Summary of procedural aspects (1) 
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Evaluation procedure is an EMEA/WHO partnership 
Opinion adopted after consultation with the WHO 
Observers/experts from WHO and authorities of 
developing countries may attend CHMP meetings
Provided they complete and sign DoI and Confidentiality 
Undertaking form
Experts and observers have no voting rights
Summary of procedural aspects (2)
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For all positive opinions adopted under Article 
58 the EMEA prepares and publishes a 
European Public Assessment Report (EPAR)
EPAR reflects the scientific conclusions on the 
Quality, Efficacy and Safety reached at the end of 
the evaluation process
Post-opinion follow-up measures are included in 
the EPAR
Summary of procedural aspects (3) 
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Steps following the CHMP Scientific Opinion





Summary of procedural aspects (4)
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Most countries of the industrialized world have 
established competent national control authorities
European Medicines Agency (EMEA), EU/London
Center for Biologics Evaluation and Research (CBER), 
FDA/USA
Paul-Ehrlich-Institut (PEI), Germany
Medicines and Healthcare products Regulatory 
Agency (MHRA), UK 
NCAs take very efficiently care for Regulation and 
Testing of Vaccines
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Many developing countries have still not established 
competent national control authorities for vaccines
WHO and EC should consider increasing funding for 
capacity building of national drug regulatory 
authorities
autonomous decisions on product registration are 
desirable 
A careful dialogue is needed with the target users of 
the Article 58 mechanism
EU awareness of specific problems due to differences 
between the EU and developing countries
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Most developing countries have still no domestic vaccine 
manufacturing capability 
Research, development work, manufacturing and 
clinical trials primarily in industrialised nations
The vast majority of Vaccine Doses are produced in 
Europe, according to EVM:
About 90% of the production from Europe
About 10% from North America
Less than 1% from rest of the world
Existing production sites in non-EU-countries should 
be maintained and improved, e.g. in India, Brazil, 
Indonesia and Cuba
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First application for a scientific opinion for a combo 
vaccine ends with withdrawal (1)
2007, a European vaccine manufacturer submitted 
the first application file to the EMEA under Article 58
Combined vaccine against diphtheria, tetanus, 
pertussis, hepatitis B, Haemophilus influenzae type b, 
Neisseria meningitidis serogroups A and C 
Indication: primary immunisation of infants in the 
first year of life and booster immunisation of young 
children during the second year of life 
Vaccine was to be used exclusively in markets 
outside the EU, primarily in Sub-Saharan Africa
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First application for a scientific opinion for a combo 
vaccine ends with withdrawal (2)
In October 2007 applicant withdrew 
application
Reasoning: Combo does not fit with the 
current WHO vaccination strategy, i.e. 
to built upon existing EPI vaccination schedule + 
monovalent meningitis A mass vaccination in 
children older than one year
At the time of withdrawal CHMP had in 
addition a few concerns
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Successful applications for a scientific opinion
For all positive opinions adopted under Article 58 the EMEA 
prepares and publishes a European Public Assessment Report 
(EPAR), which reflects the scientific conclusions reached at the 
end of the evaluation process 
Aluvia Common name: lopinavir / ritonavir  Rev. 2 
29/11/07
Lamivudine GSK Common name: Lamivudine GSK Rev. 4 
18/03/08
Lamivudine/Zidovudine GSK Common name: 
Lamivudine/zidovudine GSK Rev. 3 
18/03/08
Indicated for the treatment of HIV-1 infected adults and 
children in combination with other antiretroviral agents 
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Vaccine INN MAH 
Ambirix Inactivated hepatitis A virus, 
hepatitis B surface antigen  
GlaxoSmithKline Biologicals   
Cervarix Human Papillomavirus Vaccine 
Types 16&18 recombinant 
GlaxoSmithKline Biologicals 
Daronrix A/ Vietnam/1194/2004 (H5N1) flu 
whole virus (inactivated) 
GlaxoSmithKline Biologicals   
Dukoral Vibrio cholerae and recombinant 
cholera toxin B-submit 
SBL Vaccin AB 
Fendrix Hepatitis B (rDNA) vaccine 
(adjuvanted, adsorbed) 
GlaxoSmithKline Biologicals  
Focetria Flu virus surface antigens strain 
A/ Vietnam/1194/2004 (H5N1) 
Novartis Vaccines and 
Diagnostics 
Gardasil Human papillomavirus vaccine 
(Types 6,11,16,18) rec. adsorbed 
Sanofi Pasteur MSD 
HBVAXPRO Hepatitis B surface antigen 
(HbsAg) + Hib 
Sanofi Pasteur MSD 
 
 
The Role of the CHMP in Vaccine MA Procedures
Centrally Authorised Vaccines (1)
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Vaccine INN MAH 





Comb. vaccine (DTPa-HBV-IPV 
vaccine) 
GlaxoSmithKline Biologicals  
MMR-VaxPro Measles, mumps and rubella 
vaccine (live) 
Sanofi Pasteur MSD 
Prevenar Pneumococcal conjugate vaccine Wyeth-Lederle Vaccines S.A. 
Procomvax Haemophilus b conjugated and 
hepatitis B vaccine 
Sanofi Pasteur MSD 
Proquad Measles, mumps, rubella and 
varicella vaccine (live) 
Sanofi Pasteur MSD 
Quintanrix Comb. Vaccine (DTPw-
HBV(rDNA) and Haemophilus 
type b conjugate vaccine 
(adsorbed) 
GlaxoSmithKline Biologicals  
 
 
The Role of the CHMP in Vaccine MA Procedures
Centrally Authorised Vaccines (2)
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Vaccine INN MAH 
Rotarix Human rotavirus, live attenuated GlaxoSmithKline Biologicals 
Rotateq Rotavirus vaccine, live, oral Sanofi Pasteur MSD 
Silgard Human papillomavirus vaccine 
(Types 6,11,16,18), rec. adsorbed 
Merck, Sharp & Dohme 
Tritanrix-
HepB 
Comb. vaccine (DTPw-HBV 
vaccine) 
GlaxoSmithKline Biologicals  
Twinrix adult 
 
Comb. Hep A and B vaccine GlaxoSmithKline Biologicals  
Twinrix 
paediatric 
Comb. Hep A and B vaccine GlaxoSmithKline Biologicals  
Zostavax 
 
Zoster vaccine (live) Sanofi Pasteur MSD 
 
 
The Role of the CHMP in Vaccine MA Procedures
Centrally Authorised Vaccines (3)
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Thank you for your attention
Dr. Manfred G. Haase, Langen, Germany
